4.7 Article

Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast

Journal

EUROPEAN JOURNAL OF CANCER
Volume 50, Issue 11, Pages 1880-1890

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2014.02.023

Keywords

Breast screening; DCIS; Pathology; Radiology; Outcomes; Practice variation

Categories

Funding

  1. NHS Breast Screening Programme
  2. Director of UK Cancer Screening Programmes, CBE
  3. Pfizer UK
  4. Breast Cancer Research Trust UK
  5. National Institute for Health Research [03/DHCS/03/G121/51] Funding Source: researchfish

Ask authors/readers for more resources

Background: The Sloane Project is the largest prospective audit of ductal carcinoma in situ (DCIS) worldwide, with over 12,000 patients registered between 2003 and 2012, accounting for 50% of screen-detected DCIS diagnosed in the United Kingdom (UK) over the period of accrual. Methods: Complete multidisciplinary data from 8313 patients with screen-detected DCIS were analysed for surgical outcome in relation to key radiological and pathological parameters for the cohort and also by hospital of treatment. Adverse surgical outcomes were defined as either failed breast conservation surgery (BCS) or mastectomy for small lesions (<20 mm) (MFSL). Inter-hospital variation was analysed by grouping hospitals into high, medium and low frequency subgroups for these two adverse outcomes. Results: Patients with failed BCS or MFSL together accounted for 49% of all mastectomies. Of 6633 patients embarking on BCS, 799 (12.0%) required mastectomy. MFSL accounted for 510 (21%) of 2479 mastectomy patients. Failed BCS was associated with significant radiological under-estimation of disease extent and MFSL significant radiological over-estimation of disease extent. There was considerable and significant inter-hospital variation in failed BCS (range 3-32%) and MFSL (0-60%) of a hospital's BCS/mastectomy workload respectively. Conversely, there were no differences between the key radiological and pathological parameters in high, medium and low frequency adverse-outcome hospitals. Conclusions: This evidence suggests significant practice variation, not patient factors, is responsible for these adverse surgical outcomes in screen-detected DOTS. The Sloane Project provides an evidence base for future practice benchmarking. (C) 2014 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study

Anthony J. Maxwell, Bridget Hilton, Karen Clements, David Dodwell, Joanne Dulson-Cox, Olive Kearins, Cliona Kirwan, Janet Litherland, Senthurun Mylvaganam, Elena Provenzano, Sarah E. Pinder, Elinor Sawyer, Abeer M. Shaaban, Nisha Sharma, Hilary Stobart, Matthew G. Wallis, Alastair M. Thompson

Summary: This cohort study aimed to investigate the natural history of ductal carcinoma in situ (DCIS) by determining the outcomes of women who did not undergo surgery after being diagnosed with screen-detected DCIS. The findings suggest that active surveillance may be a reasonable alternative to surgery for patients with low-grade DCIS, but surgery should still be considered for patients with intermediate or high-grade disease.

BREAST (2022)

Article Medicine, General & Internal

Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study)

David Jenkinson, Karoline Freeman, Karen Clements, Bridget Hilton, Joanne Dulson-Cox, Olive Kearins, Nigel Stallard, Matthew G. Wallis, Nisha Sharma, Cliona Kirwan, Sarah Pinder, Elena Provenzano, Abeer M. Shaaban, Hilary Stobart, Samantha McDonnell, Alastair M. Thompson, Sian Taylor-Phillips

Summary: The National Health Service (NHS) Breast Screening Programme aims to detect cancer earlier when treatment is more effective. However, it may also harm women by over diagnosing and overtreating cancers that would never have become symptomatic. This study explores how atypia develops into breast cancer in terms of number of women, time of cancer development, cancer type and severity, and whether this varies for different types of atypia.

BMJ OPEN (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Breast calcification micromorphology classification

Robert Scott, Iain Lyburn, Eleanor Cornford, Pascaline Bouzy, Nicholas Stone, Charlene Greenwood, Ihsanne Bouybayoune, Sarah Pinder, Keith Rogers

Summary: This article proposes the development of a lexicon and classification system for the micromorphology of breast calcifications, aiming to ensure consistency and comparability in published research on this topic.

BRITISH JOURNAL OF RADIOLOGY (2022)

Article Cell Biology

The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer

Ayaka Katayama, Jane Starczynski, Michael S. Toss, Abeer M. Shaaban, Elena Provenzano, Cecily M. Quinn, Grace Callagy, Colin A. Purdie, Rebecca Millican-Slater, David Purnell, Leena Chagla, Tetsunari Oyama, Sarah E. Pinder, Steve Chan, Ian Ellis, Andrew H. S. Lee, Emad A. Rakha

Summary: The study aimed to investigate the impact of chromosome 17 alterations on the assessment of HER2 gene amplification and its correlation with neoadjuvant therapy. The results showed no significant relationship between CEP17 alterations and pCR rate in both HER2-amplified and HER2-non-amplified breast cancer. However, the histological grade of HER2-non-amplified tumors and the estrogen receptor negativity of HER2-amplified tumors were predictors of pCR.

HISTOPATHOLOGY (2022)

Article Cell Biology

Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Stephen B. Fox, Fluer Webster, Chih-Jung Chen, Boon Chua, Laura Collins, Maaria-Pia Foschini, G. Bruce Mann, Ewan Millar, Sarah E. Pinder, Emad Rakha, Abeer Shaaban, Benjamin Y. Tan, Gary Tse, Peter Watson, Puy Hoon Tan

Summary: The ICCR has developed a new international dataset for pathology reporting of DCIS, variants of LCIS, and low-grade lesions to improve patient outcomes and promote uniform global management of breast disease. The dataset comprises core and noncore elements, taking into account current evidence and practical considerations.

HISTOPATHOLOGY (2022)

Article Genetics & Heredity

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, Vandna Shah, Marlous Hoogstraat, Emi Sei, Diego Mallo, Maria Roman-Escorza, Ahmed A. Ahmed, Mingchu Xu, Alexandra W. Van den Belt-Dusebout, Wim Brugman, Anna K. Casasent, Karen Clements, Helen R. Davies, Liping Fu, Anita Grigoriadis, Timothy M. Hardman, Lorraine M. King, Marielle Krete, Petra Kristel, Michiel de Maaker, Carlo C. Maley, Jeffrey R. Marks, Brian A. Menegaz, Lennart Mulder, Frank Nieboer, Salpie Nowinski, Sarah Pinder, Jelmar Quist, Carolina Salinas-Souza, Michael Schaapveld, Marjanka K. Schmidt, Abeer M. Shaaban, Rana Shami, Mathini Sridharan, John Zhang, Hilary Stobart, Deborah Collyar, Serena Nik-Zainal, Lodewyk F. A. Wessels, E. Shelley Hwang, Nicholas E. Navin, P. Andrew Futreal, Alastair M. Thompson, Jelle Wesseling, Elinor J. Sawyer

Summary: A genomic analysis of ductal carcinoma in situ (DCIS) samples reveals that a significant portion of invasive breast cancer recurrences are unrelated to the initial DCIS and have distinct clonal origins. This finding is crucial for accurately assessing the risk of DCIS, developing effective treatment strategies, and identifying predictive biomarkers.

NATURE GENETICS (2022)

Article Genetics & Heredity

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2

Sue Philpott, Maria Raikou, Ranjit Manchanda, Michelle Lockley, Naveena Singh, Malcolm Scott, D. Gareth Evans, Julian Adlard, Munaza Ahmed, Richard Edmondson, Emma Roisin Woodward, Athena Lamnisos, Janos Balega, Angela F. Brady, Aarti Sharma, Louise Izatt, Anjana Kulkarni, Vishakha Tripathi, Joyce S. Solomons, Kevin Hayes, Helen Hanson, Katie Snape, Lucy Side, Steve Skates, Alistair McGuire, Adam N. Rosenthal

Summary: This study aimed to evaluate the effectiveness and cost-effectiveness of ovarian cancer surveillance in BRCA1/2-heterozygous women deferring risk-reducing surgery. The results showed that surveillance in a real-world setting was feasible and demonstrated similar performance to research trials, effectively down-staging ovarian cancer and saving costs.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Heather J. Bax, Jitesh Chauhan, Chara Stavraka, Aida Santaolalla, Gabriel Osborn, Atousa Khiabany, Melanie Grandits, Jacobo Lopez-Abente, Lais C. G. F. Palhares, Charleen Chan Wah Hak, Alexandra Robinson, Amy Pope, Natalie Woodman, Cristina Naceur-Lombardelli, Sadek Malas, Jack E. M. Coumbe, Mano Nakamura, Roman Laddach, Silvia Mele, Silvia Crescioli, Anna M. Black, Sara Lombardi, Silvana Canevari, Mariangela Figini, Ahmad Sayasneh, Sophia Tsoka, Kevin FitzGerald, Cheryl Gillett, Sarah Pinder, Mieke Van Hemelrijck, Rebecca Kristeleit, Sharmistha Ghosh, Ana Montes, James Spicer, Sophia N. Karagiannis, Debra H. Josephs

Summary: This study investigated the potential use of sFR alpha as a biomarker for ovarian cancer. The results showed that sFR alpha levels were significantly higher in patients compared to healthy volunteers and decreased alongside tumor burden during treatment. Additionally, high concentrations of sFR alpha reduced the effectiveness of anti-FR alpha antibodies, but this effect could be overcome by increasing antibody doses.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)

D. Gareth Evans, Lorna McWilliams, Susan Astley, Adam R. Brentnall, Jack Cuzick, Richard Dobrashian, Stephen W. Duffy, Louise S. Gorman, Elaine F. Harkness, Fiona Harrison, Michelle Harvie, Andrew Jerrison, Matthew Machin, Anthony J. Maxwell, Sacha J. Howell, Stuart J. Wright, Katherine Payne, Nadeem Qureshi, Helen Ruane, Jake Southworth, Lynne Fox, Sarah Bowers, Gillian Hutchinson, Emma Thorpe, Fiona Ulph, Victoria Woof, Anthony Howell, David P. French

Summary: The study developed BC-Predict, a risk assessment tool that collects standard risk factor information, mammographic density, and Polygenic Risk Score (PRS) to predict the risk of breast cancer. The results showed that inviting women at high and moderate risk for additional screening and preventive measures can increase the uptake of preventive medication.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England

Melissa Ruth Gannon, Min Hae Park, Katie Miller, David Dodwell, Kieran Horgan, Karen Clements, Jibby Medina, David Alan Cromwell

Summary: This study evaluated the consistency of cancer drug therapy (CDT) information in two data sources for early invasive breast cancer. The overall concordance between the two datasets was 94%, with improvement over time. Factors such as age, time of diagnosis, and healthcare institutions influenced the consistency. Combining these data sources provides a more comprehensive evaluation of CDT treatment.

CANCER EPIDEMIOLOGY (2023)

Article Oncology

Variation in Rates of Post-Mastectomy Radiotherapy Among Women with Early Invasive Breast Cancer in England and Wales: A Population- Based Cohort Study

K. Miller, M. R. Gannon, J. Medina, K. Clements, D. Dodwell, K. Horgan, M. H. Park, D. A. Cromwell

Summary: This study examined the variation of post-mastectomy radiotherapy (PMRT) patterns among women with early invasive breast cancer (EIBC) in England and Wales, and explored the influence of different patient factors on this variation.

CLINICAL ONCOLOGY (2023)

Article Oncology

Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England

Melissa Ruth Gannon, David Dodwell, Ajay Aggarwal, Min Hae Park, Katie Miller, Kieran Horgan, Karen Clements, Jibby Medina, David Alan Cromwell

Summary: Variation in the uptake of NICE-recommended oncological drugs for invasive breast cancer exists, with lowest uptake among women aged 70+ years.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang

Summary: This study explored the predictive ability of DNA damage response (DDR) and immune markers in the treatment response of triple-negative breast cancer. High immune features predict response to docetaxel, while high DDR signature scores predict response to carboplatin. Patients can be divided into different subgroups based on their treatment sensitivity. Caution is needed when using transcriptional signatures derived from primary tumors to guide treatment.

CLINICAL CANCER RESEARCH (2023)

Article Multidisciplinary Sciences

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis

Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.

NATURE COMMUNICATIONS (2023)

Article Oncology

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo

Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi

Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri

Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Impact of colorectal cancer screening on survival after metachronous metastasis

Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman

Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY)

Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia

Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study

Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond

Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.

EUROPEAN JOURNAL OF CANCER (2024)

Letter Oncology

Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity

Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction

Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen

Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li

Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Peptide absent sequences emerging in human cancers

Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares

Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.

EUROPEAN JOURNAL OF CANCER (2024)